NCT07217171View on ClinicalTrials.gov

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

PHASE1RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

January 29, 2029

Study Completion Date

January 29, 2031

Conditions
Bladder CancerSquamous Cell Carcinoma of the LungEsophageal Squamous Cell CarcinomaTongue Squamous Cell CarcinomaCutaneous Squamous Cell CancerPenile Squamous Cell CarcinomaAnal Squamous Cell CarcinomaVulvar Squamous Cell CarcinomaCervical Squamous Cell Carcinoma
Interventions
DRUG

EVOLVE104

EVOLVE104 is provided as a solution for injection via IV infusion

DRUG

EVOLVE104

Dose levels for Phase 1b will be determined based on the outcome of Phase 1a

Trial Locations (1)

49546

RECRUITING

START Midwest, Grand Rapids

All Listed Sponsors
lead

EvolveImmune United, Inc

INDUSTRY

NCT07217171 - A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | Biotech Hunter | Biotech Hunter